Data as of Sep 19
| -0.20 / -5.24%|
Rosetta Genomics Ltd. is seeking to develop and commercialize new diagnostic tests and therapeutics based on a group of genes known as microRNAs. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are believed to play an important role in normal function and in various pathologies. The company's cancer testing services are available through its Philadelphia-based CAP-accredited and CLIA-certified lab. Rosetta Genomics was founded in March 2000 by Bentwich Isaac and is headquartered in Rehovot, Israel.
|Kenneth A. Berlin||President, CEO & Head-Investor Relations|
|Ron Kalfus||Chief Financial Officer|
|Eti Meiri||Vice President-Research|
|E. Robert Wassman||Chief Medical Officer|
|Dganit Bar||Chief Scientific Officer|